Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Ng George K, holds the title of Chief Executive Officer at Processa Pharmaceuticals, Inc..
On 2026-05-29, the insider transacted 2,129 shares.The shares were transacted at a weighted average price of $2.57 per share, resulting in a total market-relevant value of $5K.
**Transaction:** buy of 2,129 shares by Ng George K (Chief Executive Officer). **Strategic Implications (Investor Edge):** This is a high-conviction open market purchase by the CEO, a strong bullish signal for a small-cap biotech. The CEO is putting his own capital at risk, which often precedes positive catalysts or reflects undervaluation. Investors should monitor for upcoming news or pipeline developments. **Key Takeaways:** - CEO bought shares on the open market, not via option exercise or 10b5-1 plan. - Purchase increased his stake by 27%, showing alignment with shareholders. - Small transaction size ($5.5k) but significant for a micro-cap CEO with limited prior holdings.
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.